Picture of Divi's Laboratories logo

DIVISLAB — Divi's Laboratories News Story

0.000.00%
in flag iconLast trade - 00:00
HealthcareConservativeLarge CapHigh Flyer

India's Divi's Laboratories up on higher Q3 profit; top Nifty Pharma gainer

** Shares of Divi's Laboratories  DIVI.NS  up 3.7% to
3,788.75 rupees, steepest rise since December 
    ** Pharma co reported ~17% rise in Q3 net profit, rev from
ops up ~9%
    ** Jefferies says it is bullish on the co, but expects
factors like improvement in pricing pressures for generics to
start unfolding only post FY26; cuts FY25E EPS by 3% 
    ** Retains "hold" with unchanged PT of 3,610 rupees 
    ** Brokerage PhillipCapital also flags ongoing margin
pressure in generics due to pricing pressures; cuts FY25 EPS by
14%, keeps rating at "neutral" with unchanged PT of 3,300 rupees
        ** Adds, co has potential to deliver surprise earnings
in upcoming quarters 
  
    ** On avg, analysts' rating equivalent to "sell", their
median PT is 3,150 rupees - ~14% discount to its last close -
LSEG
    ** Co top gainer on Nifty Pharma index  .NIPHARM , up 0.9% 
    ** Trading volume is 1.3x 30-day avg 

 (Reporting by Manvi Pant in Bengaluru)
 ((Manvi.Pant@thomsonreuters.com; +918447554364;))

Recent news on Divi's Laboratories

See all news